Daily Stock Analysis, ABEO, Abeona Therapeutics Inc, priceseries

Abeona Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
4.75
Close
4.80
High
4.95
Low
4.65
Previous Close
4.70
Daily Price Gain
0.10
YTD High
6.40
YTD High Date
Feb 15, 2017
YTD Low
4.50
YTD Low Date
Feb 1, 2017
YTD Price Change
-0.20
YTD Gain
-4.00%
52 Week High
9.44
52 Week High Date
Oct 20, 2016
52 Week Low
2.27
52 Week Low Date
May 12, 2016
52 Week Price Change
2.20
52 Week Gain
84.62%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Apr 13. 2015
3.35
Apr 15. 2015
4.00
2 Trading Days
19.25%
Link
LONG
May 5. 2015
5.97
May 28. 2015
8.69
16 Trading Days
45.64%
Link
LONG
Mar 3. 2016
2.35
Mar 23. 2016
2.72
14 Trading Days
15.63%
Link
LONG
May 20. 2016
2.49
Jun 13. 2016
2.98
15 Trading Days
19.66%
Link
LONG
Jul 28. 2016
2.56
Aug 30. 2016
4.06
23 Trading Days
58.54%
Link
LONG
Sep 1. 2016
4.29
Sep 27. 2016
5.61
17 Trading Days
30.86%
Link
LONG
Jan 3. 2017
5.00
Jan 11. 2017
5.27
6 Trading Days
5.46%
Link
Company Information
Stock Symbol
ABEO
Exchange
NasdaqCM
Company URL
http://www.abeonatherapeutics.com
Company Phone
2149055100
CEO
Timothy J. Miller
Headquarters
Texas
Business Address
3333 LEE PARKWAY, SUITE 600, DALLAS, TX 75219
Sector
Equity
Industry Category
-
Industry Group
-
CIK
0000318306
About

Abeona Therapeutics Inc. focuses on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. The company's lead programs are ABO-101 (AAV NAGLU) and ABO-102 (AAV SGSH), adeno-associated v...

Description

Abeona Therapeutics Inc. focuses on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. The company's lead programs are ABO-101 (AAV NAGLU) and ABO-102 (AAV SGSH), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (MPS IIIB and IIIA). It is also developing ABO-201 (AAV CLN3) gene therapy for juvenile Batten disease (JBD); and ABO-301 (AAV FANCC) for Fanconi anemia (FA) disorder using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. In addition, the company is developing rare plasma protein therapies, including PTB-101 SDF Alpha (alpha-1 protease inhibitor) for inherited COPD using its proprietary SDF (Salt Diafiltration) ethanol-free process. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse, for mucositis, stomatitis, aphthous ulcers, and traumatic ulcers; and ProctiGard, a mucoadhesive oral wound rinse, for the treatment of rectal mucositis and radiation proctitis. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.